ACADIA Pharmaceuticals Inc. Average Payables

Average Payables of ACAD for past 10 years: annual, quarterly and twelve month trailing (TTM) including Average Payables growth rates and interactive chart.


Highlights and Quick Summary

  • Average Payables for the quarter ending December 30, 2020 was $12.3 Million (a 525.38% increase compared to previous quarter)
  • Year-over-year quarterly Average Payables increased by 163.63%
  • Annual Average Payables for 2020 was $10.5 Million (a 138.42% increase from previous year)
  • Annual Average Payables for 2019 was $4.41 Million (a -21.26% decrease from previous year)
  • Annual Average Payables for 2018 was $5.6 Million (a -43.43% decrease from previous year)
Visit stockrow.com/ACAD for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Average Payables of ACADIA Pharmaceuticals Inc.

Most recent Average Payablesof ACAD including historical data for past 10 years.

Interactive Chart of Average Payables of ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. Average Payables for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $12.26 $1.96 $5.48 $4.65 $10.52
2019 $7.08 $3.2 $3.99 $3.14 $4.41
2018 $5.98 $2.96 $3.46 $2.58 $5.6
2017 $6.35 $2.9 $2.31 $1.74 $9.91
2016 $2.79 $2.52 $1.97 $1.91 $3.91
2015 $1.84 $1.66 $2.01 $2.04 $1.84
2014 $1.19 $1.12 $1.14 $1.48 $1.19
2013 $0.87 $1.13 $0.97 $1.22 $0.87
2012 $1.67 $1.2 $0.95 $1.21 $1.67
2011 $1.97 $1.94 $1.72 $1.75 $1.97
2010 $2.46 $2.59 $3.14 $2.46

Business Profile of ACADIA Pharmaceuticals Inc.

Sector: Healthcare
Industry: Biotechnology
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.